Malmborg A S, Ahlén S
Department of Clinical Microbiology, Huddinge University Hospital, Sweden.
Chemotherapy. 1993;39(1):32-5. doi: 10.1159/000238970.
The in vitro activity of sparfloxacin, a new fluoroquinolone, was compared with ciprofloxacin and ofloxacin against 166 consecutive isolates from the upper respiratory tract of outpatients. The strains were fully susceptible to three quinolones. The antibacterial activity of sparfloxacin was comparable or better than that of ofloxacin and ciprofloxacin against all strains. Sparfloxacin was fourfold more active against Staphylococcus aureus and Streptococcus pneumoniae. The favourable MIC values and a prolonged half-life makes sparfloxacin interesting for treating respiratory tract infections in out-patient care.
将新型氟喹诺酮类药物司帕沙星的体外活性与环丙沙星和氧氟沙星进行比较，以观察其对166株来自门诊患者上呼吸道的连续分离菌株的抗菌效果。这些菌株对三种喹诺酮类药物均完全敏感。司帕沙星对所有菌株的抗菌活性与氧氟沙星和环丙沙星相当或更佳。司帕沙星对金黄色葡萄球菌和肺炎链球菌的活性高出四倍。其良好的最低抑菌浓度值和较长的半衰期使司帕沙星在门诊治疗呼吸道感染方面颇具吸引力。
